Advertisement

Clinical and Translational Oncology

, Volume 17, Issue 11, pp 895–902 | Cite as

The differences of clinicopathological factors for breast cancer in respect to time of recurrence and effect on recurrence-free survival

  • B. B. Oven UstaaliogluEmail author
  • O. Balvan
  • A. Bilici
  • A. Develi
  • M. Aliustaoglu
  • F. A. Vardar
  • B. Erkol
Research Article

Abstract

Purpose

In the literature, small number of study has addressed time of recurrence in breast cancer. We analyzed clinicopathological factors predicting early or late recurrence in breast cancer patients and also prognostic factors related with recurrence-free survival (RFS) in recurrent patients.

Patients/methods

We evaluated retrospectively 1980 breast cancer patients. Relapsed was defined as early if it was occured first 5 year of follow-up (Group 1) and late if it was occured after 5 years (Group 2). The clinicopathological factors were compared in respect of time of recurrence. The prognostic factors were evaluated using univariate and multivariate analyses.

Results

Recurrence wase detected in 141 patient during follow-up. Tumors recurred after 5 years more likely to have lower stage (p = 0.05), tumors without lymphovascular invasion (LVI) (p < 0.001) and perineural invasion (PNI) (p = 0.01), and also HER2 negative (p < 0.001). The median RFS time and 5 years RFS rates were 42.9 months and 31.9 %, respectively. LVI (p = 0.01), PNI (p = 0.03), HER2 (p = 0.003), progesterone receptor (PR) (p = 0.04), the presence of neoadjuvant chemotherapy (p = 0.003), adjuvant hormonotherapy (p = 0.05) were found to be related with RFS. Axillary lymph node metastasis (p = 0.05) and the presence of PNI (p = 0.009) were poor prognostic factors for early recurrent group. PR-positive tumors (p = 0.001) and luminal subtypes (p = 0.03) had instances of late recurrences significantly.

Conclusions

Clinicopathological factors predicting the recurrence time in breast cancer were important to modify adjuvant therapy.

Keywords

Recurrence Breast cancer Late recurrence Recurrence-free survival 

Notes

Conflict of interest

The authors declared that they have no conflict of interest.

References

  1. 1.
    Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–7.CrossRefPubMedGoogle Scholar
  2. 2.
    Kennecke H, McArthur H, Olivotto IA, Speers C, Bajdik C, Chia SK, et al. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen. Cancer. 2008;112:1437–44.CrossRefPubMedGoogle Scholar
  3. 3.
    Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol. 1995;13:314–22.PubMedGoogle Scholar
  4. 4.
    Demicheli R, Abbattista A, Miceli R, Valagussa P, Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res Treat. 1996;41:177–85.CrossRefPubMedGoogle Scholar
  5. 5.
    Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT. Metastatic pattern in recurrent breast cancer. Special reference to intrathoracic recurrences. Cancer. 1988;62:2226–33.CrossRefPubMedGoogle Scholar
  6. 6.
    Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol. 1996;14:2738–46.PubMedGoogle Scholar
  7. 7.
    Joensuu K, Leidenius M, Kero M, Andersson LC, Horwitz KB, Heikkilä P. ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. Breast Cancer (Auckl). 2013;7:23–34.PubMedCentralPubMedGoogle Scholar
  8. 8.
    Song WJ, Kim KI, Park SH, Kwon MS, Lee TH, Park HK, et al. The Risk Factors Influencing between the Early and Late Recurrence in Systemic Recurrent Breast Cancer. J Breast Cancer. 2012;15:218–23.PubMedCentralCrossRefPubMedGoogle Scholar
  9. 9.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010;134:907–22.PubMedCentralPubMedGoogle Scholar
  10. 10.
    Early Breast Cancer Trialists’ Collaborative Group. Effects of radiotherapy and surgery in early breast cancer. N Engl J Med. 1995;333:1444–55.CrossRefGoogle Scholar
  11. 11.
    Arriagada R, Lê MG, Guinebretière JM, Dunant A, Rochard F, Tursz T. Late local recurrences in a randomised trial comparing conservative treatment with total mastectomy in early breast cancer patients. Ann Oncol. 2003;14:1617–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol. 2007;18:45–51.CrossRefPubMedGoogle Scholar
  13. 13.
    Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, Buzdar AU, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100:1179–83.CrossRefPubMedGoogle Scholar
  14. 14.
    Bosco JL, Lash TL, Prout MN, Buist DS, Geiger AM, Haque R, et al. BOW Investigators. Breast cancer recurrence in older women five to ten years after diagnosis. Cancer Epidemiol Biomarkers Prev. 2009;18:2979–83.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Takeuchi H, Tsuji K, Ueo H. Prediction of early and late recurrence in patients with breast carcinoma. Breast Cancer. 2005;12:161–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Vollenweider-Zerargui L, Barrelet L, Wong Y, Lemarchand-Béraud T, Gómez F. The predictive value of estrogen and progesterone receptors’ concentrations on the clinical behaviour of breast cancer in women. Clinical correlation on 547 patients. Cancer. 1986;57:1171–80.CrossRefPubMedGoogle Scholar
  17. 17.
    Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, et al. Locoregional recurrence in patients with HER2 positive breast cancer. Breast. 2013;22:856–62.CrossRefPubMedGoogle Scholar
  18. 18.
    Ahn SG, Lee HM, Cho SH, Bae SJ, Lee SA, Hwang SH, et al. The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence. PLoS One. 2013;8(5):e63510.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Nguyen PL, Taghian AG, Katz MS, Niemierko A, Abi Raad RF, Boon WL, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008;26:2373–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Jagsi R, Raad RA, Goldberg S, Sullivan T, Michaelson J, Powell SN, et al. Locoregional recurrence rates and prognostic factors for failure in node-negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Oncol Biol Phys. 2005;62:1035–9.CrossRefPubMedGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2015

Authors and Affiliations

  • B. B. Oven Ustaalioglu
    • 1
    Email author
  • O. Balvan
    • 2
  • A. Bilici
    • 3
  • A. Develi
    • 2
  • M. Aliustaoglu
    • 2
  • F. A. Vardar
    • 4
  • B. Erkol
    • 1
  1. 1.Department of Medical OncologyHaydarpasaNumuneEducation and Research HospitalIstanbulTurkey
  2. 2.Department of Medical OncologyDr. LutfiKirdarKartal Education and Research HospitalIstanbulTurkey
  3. 3.Department of Medical OncologyMedipol UniversityIstanbulTurkey
  4. 4.Department of PathologyHaydarpasa Numune Education and Research HospitalIstanbulTurkey

Personalised recommendations